Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorZHANG Jiaqi

About this trial

Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. It participates in oxidative reactions within the tricarboxylic acid cycle and electron transport chain, sustaining ATP synthesis and mitochondrial efficiency. Exercise influences multiple pathways of NAD metabolism, altering the NAD⁺/NADH ratio and thereby affecting energy production and fatigue resistance. Studies have shown that both aerobic exercise and NAD precursor supplementation (e.g., nicotinamide riboside \[NR\]) can elevate body NAD levels and enhance mitochondrial function, though findings remain inconsistent due to variations in dosage and participants' characteristics. This study aims to investigate how acute NR supplementation interacts with Zone 2 cycling training in adults. Specifically, it examines the temporal and dose-dependent effects of NR supplementation on metabolic flexibility and exercise performance. The results may clarify the potential synergistic benefits of combining NAD supplementation with low-intensity endurance training to improve aerobic adaptability.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Over 18 years old

BMI <30 kg/m2

Disqualifiers

Present of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders

Currently taking vitamin B supplements and/or NAD precursors

Taking medication that may affect the test results

Trial design

Design model

Crossover

Treatments tested in this trial

  • Nicotinamide Riboside (NR)

    Dietary supplement

    600 mg NR

  • Nicotinamide Riboside (NR)

    Dietary supplement

    300 mg NR

Treatment groups

16 Participants
are divided into 3 treatment groups
Group A: 600 mgExperimental treatment 1 intervention
Group B: 300 mgExperimental treatment 1 intervention
Group C: 0 mgNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Substrate utilization (CHO and fat oxidation rate)

Time frame
From enrollment to the end of treatment at 4 weeks

Secondary outcomes

1

Oxygen consumption

Time frame
From enrollment to the end of treatment at 4 weeks
2

Heart rate

Time frame
From enrollment to the end of treatment at 4 weeks
3

Blood glucose concentration

Time frame
From enrollment to the end of treatment at 4 weeks
4

Blood lactate concentration

Time frame
From enrollment to the end of treatment at 4 weeks

Other outcomes

1

Height

Time frame
From enrollment to the end of treatment at 4 weeks
2

Weight

Time frame
From enrollment to the end of treatment at 4 weeks
3

Power output at VT1

Time frame
From enrollment to the end of treatment at 4 weeks
4

Health history questionnaire

This questionnaire includes questions regarding participant's present/past history of diseases and his/her family history of diseases.

Time frame
From enrollment to the end of treatment at 4 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

ZHANG Jiaqi

Lead sponsor

Chinese University of Hong Kong

Sponsor institution